Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

计划入组 39 人 · 首次发布于 2024 年 11 月 4 日

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

计划入组 99 人 · 首次发布于 2020 年 7 月 31 日

Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

计划入组 13 人 · 首次发布于 2008 年 5 月 8 日

ARO-ATXN2

AAV-miRNA targeting Atxn2(Affinia)

ATXN2 modulator therapy(Maze Therapeutics)

Arrowhead Pharmaceuticals Receives $100 Million Milestone Payment for ARO-DM1 Myotonic Dystrophy Treatment

Maze Therapeutics Secures $190 Million to Advance Precision Medicine Programs

Arrowhead Seeks FDA Approval for Plozasiran in Familial Chylomicronemia Syndrome